Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) Net Margin: 2010-2025

Historic Net Margin for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Sep 2025 value amounting to 32.84%.

  • Ironwood Pharmaceuticals' Net Margin rose 2886.00% to 32.84% in Q3 2025 from the same period last year, while for Sep 2025 it was 38.49%, marking a year-over-year increase of 9917.00%. This contributed to the annual value of 29.25% for FY2024, which is 31341.00% up from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Net Margin stood at 32.84% for Q3 2025, which was up 18.60% from 27.69% recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Net Margin ranged from a high of 376.14% in Q2 2021 and a low of -1,014.62% during Q2 2023.
  • Over the past 3 years, Ironwood Pharmaceuticals' median Net Margin value was 3.98% (recorded in 2024), while the average stood at -97.31%.
  • In the last 5 years, Ironwood Pharmaceuticals' Net Margin plummeted by 105,276bps in 2023 and then spiked by 101,371bps in 2024.
  • Quarterly analysis of 5 years shows Ironwood Pharmaceuticals' Net Margin stood at 35.31% in 2021, then skyrocketed by 1,028bps to 45.58% in 2022, then plummeted by 23,977bps to -194.19% in 2023, then soared by 30,923bps to 115.05% in 2024, then surged by 2,886bps to 32.84% in 2025.
  • Its Net Margin stands at 32.84% for Q3 2025, versus 27.69% for Q2 2025 and -90.87% for Q1 2025.